J 2022

LncRNA PVT1 is increased in renal cell carcinoma and affects viability and migration in vitro

BOHOŠOVÁ, Júlia, Marek KAŠÍK, Adéla KUBÍČKOVÁ, Karolína TRACHTOVÁ, Michal STANÍK et. al.

Basic information

Original name

LncRNA PVT1 is increased in renal cell carcinoma and affects viability and migration in vitro

Authors

BOHOŠOVÁ, Júlia (703 Slovakia, belonging to the institution), Marek KAŠÍK (203 Czech Republic, belonging to the institution), Adéla KUBÍČKOVÁ (203 Czech Republic, belonging to the institution), Karolína TRACHTOVÁ (203 Czech Republic, belonging to the institution), Michal STANÍK (703 Slovakia, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution)

Edition

JOURNAL OF CLINICAL LABORATORY ANALYSIS, HOBOKEN, WILEY, 2022, 0887-8013

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.700

RIV identification code

RIV/00216224:14110/22:00127200

Organization unit

Faculty of Medicine

UT WoS

000783767200001

Keywords in English

diagnosis; long non-coding RNA; migration next-generation sequencing; proliferation; transcriptome

Tags

International impact, Reviewed
Změněno: 15/10/2024 14:46, Ing. Martina Blahová

Abstract

V originále

Background Renal cell carcinoma is difficult to diagnose and unpredictable in disease course and severity. There are no specific biomarkers for diagnosis and prognosis estimation feasible in clinical practice. Long non-coding RNAs (lncRNAs) have emerged as potent regulators of gene expression in recent years. Aside from their cellular role, their expression patterns could be used as a biomarker of ongoing pathology. Methods In this work, we used next-generation sequencing for global lncRNA expression profiling in tumor and non-tumor tissue of RCC patients. The four candidate lncRNAs have been further validated on an independent cohort. PVT1, as the most promising lncRNA, has also been studied using functional in vitro tests. Results Next-generation sequencing showed significant dysregulation of 1163 lncRNAs; among them top 20 dysregulated lncRNAs were AC061975.7, AC124017.1, AP000696.1, AC148477.4, LINC02437, GATA3-AS, LINC01762, LINC01230, LINC01271, LINC01187, LINC00472, AC007849.1, LINC00982, LINC01543, AL031710.1, and AC019197.1 as down-regulated lncRNAs; and SLC16A1-AS1, PVT1, LINC0887, and LUCAT1 as up-regulated lncRNAs. We observed statistically significant dysregulation of PVT1, LUCAT1, and LINC00982. Moreover, we studied the effect of artificial PVT1 decrease in renal cell line 786-0 and observed an effect on cell viability and migration. Conclusion Our results show not only the diagnostic but also the therapeutic potential of PVT1 in renal cell carcinoma.

Links

NV18-03-00554, research and development project
Name: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii
Investor: Ministry of Health of the CR
90125, large research infrastructures
Name: BBMRI-CZ III
90132, large research infrastructures
Name: NCMG II